The routine use of integrase inhibitors in sub-Saharan Africa where HIV-1 non-B viruses
predominate is limited, but evaluating their effectiveness on HIV-1 subtypes and CRFs that …

Background Although biochemical analysis of HIV-1 integrase enzyme suggested the use of
integrase inhibitors (INIs) against HIV-1C, different viral subtypes may favor different …

The World Health Organization (WHO) has put forth recommendations for the use of
integrase (IN) strand transfer inhibitors (INSTIs) to be part of the first-line combination …

Major mutations associated with HIV-I integrase inhibitors (INI) resistance are rare in INI-
naive patients. However, polymorphisms at positions that may influence the genetic barrier …

Drug resistance has been recognized in all available therapeutic class of medications for the
management of human immunodeficiency virus‐1 (HIV‐1) infected patients. This makes the …

The use of integrase inhibitors (INI) is increasing in antiretroviral therapies (ART) and INI are
not all equal regarding genetic barrier to resistance. The aim of this manuscript was to …

HIV-1 integrase (IN) is a primary target for combination antiretroviral therapy. Only a limited
number of studies report on the emergence of resistance-associated mutations (RAMs) in …

Background: The emergence of integrase strand-transfer inhibitor (INSTI) resistance-
associated mutations was examined in patients with low-level viremia after switching from …

Background HIV integrase inhibitor use is limited by low genetic barrier to resistance and
possible cross-resistance among representatives of this class of antiretrovirals. The aim of …

Objectives HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though
efficacy and resistance data for non-B subtypes are limited. Two recent trials have identified …